Knee osteoarthritis treatment drug VOLT01 effective in reducing pain, post-dose syndrome

Orthopedic Sports Medicine

Levolta Pharmaceuticals released the results of a phase II study for a potential disease modifying drug for patients with knee osteoarthritis called VOLT01 at the 2014 American College of Rheumatology Annual Meeting in Boston, Nov. 14 to 19.

In a single-center study, 32 subjects with knee osteoarthritis were randomized to receive either intravenous VOLT01 or zoledronic acid.

 

The study found that that VOLT01 significantly reduced pain as compared to ZA when measured by the change in mean Visual Analogue Scale and significantly decreased the incidence of post-dose syndrome as compared to ZA. Only 12.5 percent of patients receiving VOLT01 had PDS as compared to 56.3 percent of those who received ZA.

 

A current phase III multi-center clinical trial with in Australia will assess VOLT01 for controlling knee osteoarthritis with results expected in 2015.

More articles on orthopedics:

Dr. Patricia McDougall Schick joins Prevea Regional Orthopedic Center
AAOS census: 5 most common orthopedist specialty areas
American Society for Surgery of the Hand honors Dr. Mark Vitale

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers

Most Read - Sports Medicine